comparemela.com

Page 16 - ஆக்ஸ்ஃபர்ட் அறிவியல் கண்டுபிடிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PQShield publishes white paper series to educate business leaders on the quantum threat to information security

PQShield publishes white paper series to educate business leaders on the quantum threat to information security PQShield, the cybersecurity company specialising in post-quantum cryptography, has today published a series of white papers explaining the quantum threat to information security and outlining the solutions that will help organisations to protect their sensitive information for the future. When full-scale quantum computers arrive, they will be able to break the public-key encryption widely relied on to protect sensitive data, accessing all digital information - past, present and future. Knowing the sheer scale of the quantum security threat, engineers and scientists around the world have been working to develop a new generation of encryption - post-quantum cryptography - that will enable organisations to protect their sensitive data now and for years to come.

SpyBiotech raises $32 5M in Series A funding and appoints Lutz B Giebel as Chairman to support

Press release content from Globe Newswire. The AP news staff was not involved in its creation. SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support . SpyBiotechFebruary 10, 2021 GMT SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and display” vaccine platform technology Braavos Investment Advisers led the round, joined by new investor Oxford Investment Consultants; founding investors Oxford Sciences Innovation and GV also participated Lutz B. Giebel joins as Chairman, strengthening governance as company expands clinical development and builds operational resource ADVERTISEMENT OXFORD, United Kingdom, Feb. 10, 2021 (GLOBE NEWSWIRE) SpyBiotech, a British biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces it has raised $32.5 million in Series A equity financing and appointed Lutz B. Giebel as Chairma

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.